The #Valeant Implosion Continues (We Warned You) | $VRX

Takeaway: We were early on this one but feel vindicated.

The #Valeant Implosion Continues (We Warned You) | $VRX - Ackman cartoon 10.26.2015


Hedgeye has long been skeptical about Valeant Pharmaceuticals (VRX). Last summer, before the barrage of bad news broke for the company, we issued a comprehensive Black Book laying out the short case. In it, our Healthcare analyst Tom Tobin highlighted Valeant's unsustainable business model.


Incidentally, Tobin's team sent subscribers an update just now explaining why they believe the stock may fall another 75% from here.


CLICK HERE to access their original institutional research report.


Fast forward to today... In the most recent deluge of bad news for Valeant and hedge fund manager/shareholder Bill Ackman, Congress is now getting involved. Not a good sign. Apparently, a bipartisan special committee has been put together to “better understand [Valeant’s] drug pricing” (sic “price gouging”). In addition, it was disclosed earlier today that Bill Ackman sent a letter to Valeant CEO warning that his reputation is at "grave risk" and Valeant is at risk of becoming "toxic."


Talk about being a day late and a dollar short. Shares of VRX are down 14.6% today on the news.


But that's not the worst of it for Ackman. Since March, when his hedge fund Pershing Square Capital first disclosed it's 5.7% stake in Valeant, the stock has fallen 54%.


The #Valeant Implosion Continues (We Warned You) | $VRX - 11 5 2015 valeant chart


Our Healthcare team warned subscribers of the many “underappreciated risks” we saw in the stock. From the report:


“Valeant is operating what we believe is an unsustainable business model of serial acquisitions and underinvestment, fueled by debt, that will continue to lead to deterioration in the ongoing business.”


The #Valeant Implosion Continues (We Warned You) | $VRX - vrx tobin 1


In October, the stock got hammered after Citron Research released its research note comparing the drug maker to Enron. Here's what Hedgeye Healthcare analyst Andrew Freedman had to say shortly afterwards:


“It was only a matter of time before Valeant’s debt-fueled acquisition binge would come to an end.  If you look at what the underlying assets are worth and subtract the debt, you get an equity value that is closer to $20.



We spent the better part of six months researching Valeant, and there were no shortage of red flags. To name a few: Alternative pharmacy channels, inventory accounting on the Aesthetics assets, FDA investigations, price increases and questionable organic growth rates…


Trying to reconstruct the financials of Valeant’s business was near impossible given the acquisitions/divestitures and number of reclassifications… a huge part of the long thesis was a “Trust Me” story with management and that didn’t cut it with us.”


The #Valeant Implosion Continues (We Warned You) | $VRX - vrx tobin 2


And then... Ackman came to the rescue! On that fateful October day, with VRX shares down as much as 20%, he rushed onto CNBC proclaiming to the world that he bought another 2 million shares. The stock bounced 10% the following hour.


But the story obviously doesn't end there.


Much of the recent VRX criticism has been focused on the drug maker's questionable relationship with the specialty pharmacy Philidor, which Valeant may have used to artificially inflate prices. Valeant has denied these allegations, but announced last week that it would sever its ties with Philidor, noting that Philidor accounted for only about 7% of its revenues.




Here's Hedgeye CEO Keith McCullough today on the VRX “shenanigans.”


“There was a day when a $2.5B Hedge fund [position] blowing up was news. Ackman had a $2.5B position crash - and CNBC doesn't report it. This Ackman crash is going to ripple through the hedge fund community. They did everything, literally, to try to prop up $VRX - sucked little guys into buying it ... and Kaboom!”


The #Valeant Implosion Continues (We Warned You) | $VRX - vrx mccullough 1

Another French Revolution?

"Don't be complacent," writes Hedgeye Managing Director Neil Howe. "Tectonic shifts are underway in France. Is there the prospect of the new Sixth Republic? C'est vraiment possible."

read more

Cartoon of the Day: The Trend is Your Friend

"All of the key trending macro data suggests the U.S. economy is accelerating," Hedgeye CEO Keith McCullough says.

read more

A Sneak Peek At Hedgeye's 2017 GDP Estimates

Here's an inside look at our GDP estimates versus Wall Street consensus.

read more

Cartoon of the Day: Green Thumb

So far, 64 of 498 companies in the S&P 500 have reported aggregate sales and earnings growth of 6.1% and 16.8% respectively.

read more

Europe's Battles Against Apple, Google, Innovation & Jobs

"“I am very concerned the E.U. maintains a battle against the American giants while doing everything possible to sustain so-called national champions," writes economist Daniel Lacalle. "Attacking innovation doesn’t create jobs.”

read more

An Open Letter to Pandora Management...

"Please stop leaking information to the press," writes Hedgeye Internet & Media analyst Hesham Shaaban. "You are getting in your own way, and blowing up your shareholders in the process."

read more

A 'Toxic Cocktail' Brewing for A Best Idea Short

The first quarter earnings pre-announcement today is not the end of the story for Mednax (MD). Rising labor costs and slowing volume is a toxic cocktail...

read more

Energy Stocks: Time to Buy? Here's What You Need to Know

If you're heavily-invested in Energy stocks it's been a heck of a year. Energy is the worst-performing sector in the S&P 500 year-to-date and value investors are now hunting for bargains in the oil patch. Before you buy, here's what you need to know.

read more

McCullough: ‘My 1-Minute Summary of My Institutional Meetings in NYC Yesterday’

What are even some of the smartest investors in the world missing right now?

read more

Cartoon of the Day: Political Portfolio Positioning

Leave your politics out of your portfolio.

read more

Jim Rickards Answers the Hedgeye 21

Bestselling author Jim Rickards says if he could be any animal he’d be a T-Rex. He also loves bonds and hates equities. Check out all of his answers to the Hedgeye 21.

read more

Amazon's New 'Big Idea': Ignore It At Your Own Peril

"We all see another ‘big idea’ out of Amazon (or the press making one up) just about every day," writes Retail Sector Head Brian McGough. "But whatever you do, DON’T ignore this one!"

read more